Cervical cancer is a major global health issue, ranking as the fourth most common cancer in
women worldwide. Depending on stage, histology, and patient factors, the standard …

Approximately 12% of human cancers worldwide are associated with infectious agents,
which are classified by the International Agency for Research on Cancer (IARC) as Group 1 …

Human papillomaviruses, particularly high-risk human papillomaviruses, have been
universally considered to be associated with the oncogenesis and progression of various …

In The Lancet Oncology, Hitt Sharma and colleagues1 report findings from a pivotal phase
2/3 human papillomavirus (HPV) prophylactic vaccine trial. Briefly, they show that two doses …

Although HPV vaccines are highly efficacious, a notable proportion of quadrivalent
vaccinees are HPV18 seronegative post-vaccination. We have investigated this findings' …

Justification In view of new developments in vaccinology and the availability of new
vaccines, there is a need to revise/review the existing immunization recommendations …

Human papillomavirus (HPV) prophylactic vaccines were first licensed in 2006 with the
primary goal of preventing HPV-related cancers, with cervical cancer accounting for the …

Despite the introduction of Pap testing for screening to prevent cervical cancer in the mid-
20th century, cervical cancer remains a common cause of cancer-related mortality and …

During acute respiratory infections, women may concurrently receive human papillomavirus
(HPV) and respiratory vaccines, as observed during the coronavirus disease 2019 (COVID …

Human papillomavirus (HPV), a common cause of sexually transmitted diseases, may cause
warts and lead to various types of cancers, which makes it important to understand the risk …